During the secondary analysis, the less conservative but clinically meaningful criterion of steady reaction (defined as a 50% or more reduction in MADRS from baseline for two weeks) was used. In the patients who attained secure response, 25.8% in the esketamine group and 57.6% during the placebo group relapsed, with https://wardq758git1.ssnblog.com/profile